open access

Vol 29, No 4 (2022)
Review Article
Submitted: 2021-07-29
Accepted: 2022-05-14
Published online: 2022-05-30
Get Citation

Heart failure with preserved ejection fraction update: A review of clinical trials and new therapeutic considerations

Andrii Maryniak1, Nodari Maisuradze1, Rafsan Ahmed1, Patrick Biskupski2, Joseph Jayaraj1, Adam S. Budzikowski3
DOI: 10.5603/CJ.a2022.0051
·
Pubmed: 35762077
·
Cardiol J 2022;29(4):670-679.
Affiliations
  1. Department of Medicine, State University of New York: Downstate Medical Center, Brooklyn, NY, United States
  2. Department of Medicine, Lincoln Medical Center, Bronx, NY, United States
  3. Division of Cardiology, Department of Medicine, State University of New York: Downstate Medical Center, Brooklyn, NY, United States

open access

Vol 29, No 4 (2022)
Review articles — Clinical cardiology
Submitted: 2021-07-29
Accepted: 2022-05-14
Published online: 2022-05-30

Abstract

Between 2013 and 2016 there were approximately 6.2 million adults in the United States living with heart failure; nearly half had an ejection fraction that was preserved. Despite the high prevalence of heart failure with preserved ejection fraction (HFpEF), our understanding of this disease is limited and it still carries significant morbidity and mortality worldwide. At present, physicians are burdened by the inconclusive benefits of currently available treatment options. Recently the scientific community has seen an influx of new pathophysiology studies and outcome trials that have reshaped our understanding of HFpEF as a complex, multi-systemic disease. Pharmacological trials involving beta-blockers, angiotensin II receptor antagonists, aldosterone antagonists, and angiotensin-neprilysin inhibitors have demonstrated encouraging results, but have yet to reach the significance of advancements made in the treatment of heart failure with reduced ejection fraction. This review aims to summarize landmark clinical trials that have influenced current treatment guidelines, and reports on emerging evidence supporting/refuting new treatment modalities including pharmacotherapy, lifestyle modification and device therapy.

Abstract

Between 2013 and 2016 there were approximately 6.2 million adults in the United States living with heart failure; nearly half had an ejection fraction that was preserved. Despite the high prevalence of heart failure with preserved ejection fraction (HFpEF), our understanding of this disease is limited and it still carries significant morbidity and mortality worldwide. At present, physicians are burdened by the inconclusive benefits of currently available treatment options. Recently the scientific community has seen an influx of new pathophysiology studies and outcome trials that have reshaped our understanding of HFpEF as a complex, multi-systemic disease. Pharmacological trials involving beta-blockers, angiotensin II receptor antagonists, aldosterone antagonists, and angiotensin-neprilysin inhibitors have demonstrated encouraging results, but have yet to reach the significance of advancements made in the treatment of heart failure with reduced ejection fraction. This review aims to summarize landmark clinical trials that have influenced current treatment guidelines, and reports on emerging evidence supporting/refuting new treatment modalities including pharmacotherapy, lifestyle modification and device therapy.

Get Citation

Keywords

heart failure, heart failure with preserved ejection fraction, HFpEF, diastolic heart failure, clinical trials

About this article
Title

Heart failure with preserved ejection fraction update: A review of clinical trials and new therapeutic considerations

Journal

Cardiology Journal

Issue

Vol 29, No 4 (2022)

Article type

Review Article

Pages

670-679

Published online

2022-05-30

Page views

2607

Article views/downloads

809

DOI

10.5603/CJ.a2022.0051

Pubmed

35762077

Bibliographic record

Cardiol J 2022;29(4):670-679.

Keywords

heart failure
heart failure with preserved ejection fraction
HFpEF
diastolic heart failure
clinical trials

Authors

Andrii Maryniak
Nodari Maisuradze
Rafsan Ahmed
Patrick Biskupski
Joseph Jayaraj
Adam S. Budzikowski

References (63)
  1. Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019; 124(11): 1598–1617.
  2. Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-Specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016; 134(1): 73–90.
  3. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016; 18(8): 891–975.
  4. Heidenreich PA, Bozkurt B, Aguilar O, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022; 28(5): e1–e167.
  5. Reddy YNV, Borlaug BA. Heart failure with preserved ejection fraction. Curr Probl Cardiol. 2016; 41(4): 145–188.
  6. Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020; 141(9): e139–e596.
  7. Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015; 175(6): 996–1004.
  8. Tsao CW, Lyass A, Enserro D, et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail. 2018; 6(8): 678–685.
  9. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017; 14(10): 591–602.
  10. Tomasoni D, Adamo M, Anker MS, et al. Heart failure in the last year: progress and perspective. ESC Heart Fail. 2020 [Epub ahead of print].
  11. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014; 11(9): 507–515.
  12. Borlaug BA, Kass DA. Invasive hemodynamic assessment in heart failure. Cardiol Clin. 2011; 29(2): 269–280.
  13. Borlaug BA, Olson TP, Lam CSP, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010; 56(11): 845–854.
  14. Borlaug BA, Kass DA. Mechanisms of diastolic dysfunction in heart failure. Trends Cardiovasc Med. 2006; 16(8): 273–279.
  15. Westermann D, Kasner M, Steendijk P, et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation. 2008; 117(16): 2051–2060.
  16. Phan TT, Abozguia K, Nallur Shivu G, et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol. 2009; 54(5): 402–409.
  17. Tan YuT, Wenzelburger F, Lee E, et al. The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol. 2009; 54(1): 36–46.
  18. Hidalgo C, Granzier H. Tuning the molecular giant titin through phosphorylation: role in health and disease. Trends Cardiovasc Med. 2013; 23(5): 165–171.
  19. Phan TT, Abozguia K, Shivu GN, et al. Increased atrial contribution to left ventricular filling compensates for impaired early filling during exercise in heart failure with preserved ejection fraction. J Card Fail. 2009; 15(10): 890–897.
  20. Melenovsky V, Hwang SJ, Lin G, et al. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J. 2014; 35(48): 3452–3462.
  21. Haykowsky MJ, Kouba EJ, Brubaker PH, et al. Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Cardiol. 2014; 113(7): 1211–1216.
  22. Reddy YNV, Carter RE, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018; 138(9): 861–870.
  23. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019; 40(40): 3297–3317.
  24. Segar MW, Patel KV, Berry JD, et al. Generalizability and implications of the HFPEF score in a cohort of patients with heart failure with preserved ejection fraction. Circulation. 2019; 139(15): 1851–1853.
  25. Myhre PL, Vaduganathan M, Claggett BL, et al. Application of the H FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. Eur J Heart Fail. 2019; 21(10): 1288–1291.
  26. Selvaraj S, Myhre PL, Vaduganathan M, et al. Application of diagnostic algorithms for Heart Failure with preserved ejection fraction to the community. JACC Heart Fail. 2020; 8(8): 640–653.
  27. Barandiarán Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca HP, et al. Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction. Eur J Heart Fail. 2020; 22(3): 413–421.
  28. Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26(3): 215–225.
  29. Conraads VM, Metra M, Kamp O, et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail. 2012; 14(2): 219–225.
  30. Yamamoto K, Origasa H, Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail. 2013; 15(1): 110–118.
  31. Yusuf S, Pfeffer M, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362(9386): 777–781.
  32. Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006; 27(19): 2338–2345.
  33. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008; 359(23): 2456–2467.
  34. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370(15): 1383–1392.
  35. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015; 131(1): 34–42.
  36. Desai AS, Liu J, Pfeffer MA, et al. Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial. J Card Fail. 2018; 24(5): 313–320.
  37. Redfield MM, Anstrom KJ, Levine JA, et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med. 2015; 373(24): 2314–2324.
  38. Wagdy K, Hassan M. NEAT HFpEF: Organic nitrates fail to deliver. Glob Cardiol Sci Pract. 2016; 2016(1): e201601.
  39. Oeser C. Heart failure: Nitrates reduce activity levels in HFpEF. Nat Rev Cardiol. 2016; 13(1): 2.
  40. Tsujimoto T, Kajio H. Use of nitrates and risk of cardiovascular events in patients with heart failure with preserved ejection fraction. Mayo Clin Proc. 2019; 94(7): 1210–1220.
  41. Borlaug BA, Anstrom KJ, Lewis GD, et al. Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial. JAMA. 2018; 320(17): 1764–1773.
  42. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019; 381(17): 1609–1620.
  43. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.
  44. McMurray JJV, Jackson AM, Lam CSP, et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation. 2020; 141(5): 338–351.
  45. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383(15): 1413–1424.
  46. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21): 1995–2008.
  47. Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021; 27(11): 1954–1960.
  48. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; 385(16): 1451–1461.
  49. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021; 384(2): 129–139.
  50. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021; 384(2): 117–128.
  51. SOTAGLIFLOZIN shows benefit for difficult-to-treat form of heart failure [Internet]. American College of Cardiology. 2021. https://www.acc.org/about-acc/press-releases/2021/05/17/03/52/sotagliflozin-shows-benefit-for-difficult-to-treat-form-of-heart-failure (Cited 2022 May 1).
  52. Solomon SD, Vaduganathan M, L Claggett B, et al. Sacubitril/Valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020; 141(5): 352–361.
  53. Bozkurt B, Ezekowitz J. Substance and substrate: LVEF and sex subgroup analyses of PARAGON-HF and PARADIGM-HF trials. Circulation. 2020; 141(5): 362–366.
  54. Novartis Entresto® granted expanded indication in chronic heart failure by FDA. MultiVu. https://www.multivu.com/players/English/8848351-novartis-entresto-fda-approval/ (Accessed March 29, 2021).
  55. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; February 2021.
  56. Mueller S, Winzer EB, Duvinage A, et al. Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2021; 325(6): 542–551.
  57. Pandey A, Kitzman DW. Searching for the optimal exercise training regimen in heart failure with preserved ejection fraction. JAMA. 2021; 325(6): 537–539.
  58. Hasenfuß G, Hayward C, Burkhoff D, et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet. 2016; 387(10025): 1298–1304.
  59. Kaye DM, Hasenfuß G, Neuzil P, et al. One-Year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction. Circ Heart Fail. 2016; 9(12): e003662.
  60. Feldman T, Mauri L, Kahwash R, et al. Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF i [reduce elevated left atrial pressure in patients with heart failure]): a phase 2, randomized, sham-controlled trial. Circulation. 2018; 137(4): 364–375.
  61. Shah SJ, Feldman T, Ricciardi MJ, et al. One-Year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure (REDUCE LAP-HF I) trial: a randomized clinical trial. JAMA Cardiol. 2018; 3(10): 968–977.
  62. Obokata M, Reddy YNV, Shah SJ, et al. Effects of interatrial shunt on pulmonary vascular function in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2019; 74(21): 2539–2550.
  63. Berry N, Mauri L, Feldman T, et al. Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II). Am Heart J. 2020; 226: 222–231.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl